EcoDrugPlus

Protein Kinase C Zeta Type-Like

Ensembl ID : ENSAOCG00000008812
Gene Symbol: LOC111572559
3 Cross references
205 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSAOCG00000007264
Gene Symbol: PRKD3
4 Cross references
207 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSAOCG00000004149
Gene Symbol: PRKD3
3 Cross references
218 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSAOCG00000013513
Gene Symbol: PRKDC
3 Cross references
187 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSAOCG00000016839
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSAOCG00000023071
Gene Symbol: PTK2
4 Cross references
241 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSAOCG00000024168
Gene Symbol: PTK2B
3 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSAOCG00000012109
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSAOCG00000018719
Gene Symbol: PTPRB
4 Cross references
193 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSAOCG00000005134
Gene Symbol: PTPRB
4 Cross references
200 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSAOCG00000007478
Gene Symbol: LOC111588285
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSAOCG00000008707
Gene Symbol: LOC111567104
3 Cross references
160 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).